FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130486988> ?p ?o ?g. }

• W2130486988 endingPage "189" @default.
• W2130486988 startingPage "185" @default.
• W2130486988 abstract "A total of 27 patients with advanced previously untreated non-small-cell lung cancer were treated with paclitaxel and ifosfamide. The starting dose of paclitaxel was 175 mg/m2 given for 3 h by intravenous infusion on day 1. Ifosfamide 4 g/m2 was given for 4 h by intravenous infusion on day 2. Dosage of the two drugs was modified according to nadir white blood count after each cycle. Involved in the treatment were 17 males and 10 female patients. The median age was 61 years (range 47–71 years) and the median Karnofsky performance status was 70% (range 60–90%), 13 cases were stage IIIb and 14 cases were stage IV. One case was not evaluable due to lost follow-up after a single dose of chemotherapy. There were five cases not determined due to a timing error. Of 21 evaluable cases, eight achieved partial response (PR 38%, confidence interval 18.1–61.5%), seven achieved stable disease, two had a minor response. The median survival time of the whole group was 255 days (range from 38 to 567 days). The major toxicities were myalgia, arthralgia and neuropathies. Throughout the study, only three cases (15%) were treated at dose level 0. After the first cycle, 18 cases were treated at dose level 1, after a second cycle, 13 cases were treated at dose level 2. Three cases with grade 3 leukopenia were seen at dose level 0. At dose level 1, two cases had grade 3 leukopenia. At dose level 2, four episodes of grade 3 leukopenia were noted. It is concluded that paclitaxel can be combined safely with ifosfamide at these dosage levels. The response rates were comparable to the other chemotherapy combination in advanced non-small-cell lung cancer. The survival results were acceptable and comparable to the cisplatin-containing regimen. This study indicates that combinations of paclitaxel and/or ifosfamide with other agents, such as gemcitabine and vinorelbine, should be explored." @default.
• W2130486988 created "2016-06-24" @default.
• W2130486988 creator A5008578055 @default.
• W2130486988 date "1998-03-01" @default.
• W2130486988 modified "2023-09-26" @default.
• W2130486988 title "Phase II study of paclitaxel (Taxol®) and ifosfamide (Holoxan®) in inoperable non-small-cell lung cancer1This paper was presented at the 8th World Conference on Lung Cancer, Dublin, Ireland, August 10–15, 1997. Abstract no. 78.1" @default.
• W2130486988 cites W1845622004 @default.
• W2130486988 cites W1984587636 @default.
• W2130486988 cites W2011447881 @default.
• W2130486988 cites W2049190121 @default.
• W2130486988 cites W2057157978 @default.
• W2130486988 cites W2164545962 @default.
• W2130486988 cites W2275827949 @default.
• W2130486988 cites W2408773304 @default.
• W2130486988 cites W2413182551 @default.
• W2130486988 cites W2416543661 @default.
• W2130486988 cites W2419134794 @default.
• W2130486988 cites W2462775402 @default.
• W2130486988 doi "https://doi.org/10.1016/s0169-5002(97)00085-8" @default.
• W2130486988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9631366" @default.
• W2130486988 hasPublicationYear "1998" @default.
• W2130486988 type Work @default.
• W2130486988 sameAs 2130486988 @default.
• W2130486988 citedByCount "2" @default.
• W2130486988 crossrefType "journal-article" @default.
• W2130486988 hasAuthorship W2130486988A5008578055 @default.
• W2130486988 hasConcept C126322002 @default.
• W2130486988 hasConcept C126894567 @default.
• W2130486988 hasConcept C141071460 @default.
• W2130486988 hasConcept C2776256026 @default.
• W2130486988 hasConcept C2776694085 @default.
• W2130486988 hasConcept C2776907518 @default.
• W2130486988 hasConcept C2777063308 @default.
• W2130486988 hasConcept C2777292972 @default.
• W2130486988 hasConcept C2777506904 @default.
• W2130486988 hasConcept C2778119113 @default.
• W2130486988 hasConcept C2780376820 @default.
• W2130486988 hasConcept C2780873365 @default.
• W2130486988 hasConcept C71924100 @default.
• W2130486988 hasConcept C90924648 @default.
• W2130486988 hasConceptScore W2130486988C126322002 @default.
• W2130486988 hasConceptScore W2130486988C126894567 @default.
• W2130486988 hasConceptScore W2130486988C141071460 @default.
• W2130486988 hasConceptScore W2130486988C2776256026 @default.
• W2130486988 hasConceptScore W2130486988C2776694085 @default.
• W2130486988 hasConceptScore W2130486988C2776907518 @default.
• W2130486988 hasConceptScore W2130486988C2777063308 @default.
• W2130486988 hasConceptScore W2130486988C2777292972 @default.
• W2130486988 hasConceptScore W2130486988C2777506904 @default.
• W2130486988 hasConceptScore W2130486988C2778119113 @default.
• W2130486988 hasConceptScore W2130486988C2780376820 @default.
• W2130486988 hasConceptScore W2130486988C2780873365 @default.
• W2130486988 hasConceptScore W2130486988C71924100 @default.
• W2130486988 hasConceptScore W2130486988C90924648 @default.
• W2130486988 hasIssue "3" @default.
• W2130486988 hasLocation W21304869881 @default.
• W2130486988 hasLocation W21304869882 @default.
• W2130486988 hasOpenAccess W2130486988 @default.
• W2130486988 hasPrimaryLocation W21304869881 @default.
• W2130486988 hasRelatedWork W13712492 @default.
• W2130486988 hasRelatedWork W2028279018 @default.
• W2130486988 hasRelatedWork W2060746998 @default.
• W2130486988 hasRelatedWork W2083264474 @default.
• W2130486988 hasRelatedWork W2093749063 @default.
• W2130486988 hasRelatedWork W2270672625 @default.
• W2130486988 hasRelatedWork W2309555766 @default.
• W2130486988 hasRelatedWork W2396672633 @default.
• W2130486988 hasRelatedWork W2428528889 @default.
• W2130486988 hasRelatedWork W1993277780 @default.
• W2130486988 hasVolume "19" @default.
• W2130486988 isParatext "false" @default.
• W2130486988 isRetracted "false" @default.
• W2130486988 magId "2130486988" @default.
• W2130486988 workType "article" @default.